Medicus Pharma (MDCX) Income from Non-Controlling Interests (2025 - 2026)
Medicus Pharma's (MDCX) quarterly Income from Non-Controlling Interests came in at -$225.0 in Q4 2025, down 192.21% on a QoQ basis from -$77.0 in Q3 2025.
Medicus Pharma (MDCX) Income from Non-Controlling Interests (2025 - 2026) Analysis & Trends
Medicus Pharma (MDCX) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$225.0 in Q4 2025.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$225.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$302.0 (changed N/A YoY) and the FY2025 annual result came in at -$150.0, changed N/A from the prior year.
- Income from Non-Controlling Interests fell to -$225.0 in Q4 2025, from -$77.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$77.0 in Q3 2025 to a low of -$225.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 10.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 741.95 Mn |
| 10 | Medicus Pharma | 14.88 Mn | -298,205.43 | - | -66,722.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -66,722.00 |
| Dec 31, 2025 | -225.00 |
| Sep 30, 2025 | -77.00 |